MX2021010192A - Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos. - Google Patents

Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos.

Info

Publication number
MX2021010192A
MX2021010192A MX2021010192A MX2021010192A MX2021010192A MX 2021010192 A MX2021010192 A MX 2021010192A MX 2021010192 A MX2021010192 A MX 2021010192A MX 2021010192 A MX2021010192 A MX 2021010192A MX 2021010192 A MX2021010192 A MX 2021010192A
Authority
MX
Mexico
Prior art keywords
drug
ligand
drug conjugates
methylene carbamate
targeted
Prior art date
Application number
MX2021010192A
Other languages
English (en)
Inventor
Scott Jeffrey
Robert Kolakowski
Patrick J Burke
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2021010192A publication Critical patent/MX2021010192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona conjugados de ligando-fármaco y compuestos de fármaco-enlazador que comprenden una unidad de carbamato de metileno. La invención proporciona, inter alia, conjugados de ligando-fármaco, en donde el conjugado de ligando-fármaco está comprendido de una unidad de montaje auto-inmoladora que tiene una unidad de carbamato de metileno para la conjugación de un fármaco a un ligando de dirección, métodos para preparar y usarlos e intermediarios de los mismos. Los conjugados de ligando-fármaco de la presente invención son estables en circulación, aún capaces de infligir la muerte celular una vez que el fármaco libre se libera de un conjugado en la vecindad o dentro de las células tumorales.
MX2021010192A 2013-12-19 2016-06-06 Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos. MX2021010192A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361918539P 2013-12-19 2013-12-19
TW103144705A TWI727919B (zh) 2013-12-19 2014-12-19 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物

Publications (1)

Publication Number Publication Date
MX2021010192A true MX2021010192A (es) 2021-09-21

Family

ID=60450371

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016007364A MX2016007364A (es) 2013-12-19 2014-12-19 Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos.
MX2021010192A MX2021010192A (es) 2013-12-19 2016-06-06 Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016007364A MX2016007364A (es) 2013-12-19 2014-12-19 Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos.

Country Status (13)

Country Link
US (2) US11116847B2 (es)
JP (4) JP6701077B2 (es)
KR (3) KR20220127364A (es)
CN (3) CN111558049B (es)
AU (3) AU2014369019B2 (es)
CA (1) CA2932647C (es)
IL (5) IL290330B2 (es)
MX (2) MX2016007364A (es)
NZ (1) NZ721877A (es)
SG (1) SG11201610465PA (es)
TW (1) TWI727919B (es)
WO (1) WO2015095755A1 (es)
ZA (2) ZA201604564B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
CA2954934C (en) 2014-06-30 2023-09-26 Glykos Finland Oy Drug derivative and conjugates
EP3265474A1 (en) 2015-03-05 2018-01-10 Sirenas LLC Cyclic peptide analogs and conjugates thereof
EP3380126A4 (en) 2015-11-25 2019-07-24 LegoChem Biosciences, Inc. ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS
JP6949732B2 (ja) 2015-11-25 2021-10-13 レゴケム バイオサイエンシズ， インク．Ｌｅｇｏｃｈｅｍ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自壊性基を含む複合体及びそれに関連した方法
JP7120765B2 (ja) 2015-11-25 2022-08-17 レゴケム バイオサイエンシズ， インク． ペプチド基を含む複合体及びそれに関連する方法
AU2017238246B2 (en) * 2016-03-24 2021-04-01 The Administrators Of The Tulane Educational Fund Conjugates of tacrolimus, their compositions, and their uses
EA201892040A1 (ru) * 2016-03-25 2019-04-30 Сиэтл Дженетикс, Инк. Способ получения пегилированных соединений лекарственный препарат - линкер и их промежуточных соединений
EP3474901A1 (en) 2016-06-27 2019-05-01 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
CN109562152B (zh) * 2016-08-09 2024-04-02 西雅图基因公司 含有具有改善的生理化学性质的自稳定性接头的药物缀合物
WO2018045245A1 (en) 2016-09-02 2018-03-08 Sirenas Llc Cyclic peptide analogs and conjugates thereof
KR20190074292A (ko) 2016-10-18 2019-06-27 시애틀 지네틱스, 인크. 니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달
AU2017345454A1 (en) 2016-10-19 2019-05-30 Invenra Inc. Antibody constructs
FR3060567B1 (fr) * 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
MX2019007019A (es) 2016-12-22 2019-08-16 Univ Degli Studi Magna Graecia Catanzaro Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer.
WO2018124758A2 (ko) * 2016-12-28 2018-07-05 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
KR102085798B1 (ko) * 2016-12-28 2020-03-06 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
KR20240110082A (ko) 2017-02-28 2024-07-12 이뮤노젠 아이엔씨 자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체
EP4011396A1 (en) * 2017-03-10 2022-06-15 QuiaPEG Pharmaceuticals AB Releasable conjugates
CA3056134A1 (en) 2017-03-24 2018-09-27 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
MX2019011655A (es) 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
MA51189A (fr) 2017-04-27 2020-03-04 Seattle Genetics Inc Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé
JP7348071B2 (ja) * 2017-05-02 2023-09-20 レヴォリューション・メディスンズ，インコーポレイテッド ｍＴＯＲ阻害剤としてのラパマイシン類似体
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
KR20200061376A (ko) 2017-09-29 2020-06-02 다이이찌 산쿄 가부시키가이샤 항체-피롤로벤조디아제핀 유도체 콘쥬게이트
EP3700540A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS OF DEPRODUCTION FROM CD117 + CELLS
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
CA3084667A1 (en) 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
KR20200104352A (ko) * 2017-12-21 2020-09-03 파마시틱스 비.브이. 약물의 경구 생체이용률을 향상시키는 방법
US10933069B2 (en) 2018-01-05 2021-03-02 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2019171358A1 (en) * 2018-03-09 2019-09-12 Quiapeg Pharmaceuticals Ab Releasable antibody conjugates
JP7430643B2 (ja) * 2018-04-06 2024-02-13 シージェン インコーポレイテッド カンプトテシンペプチドコンジュゲート
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, C28-, and C-32-linked rapamycin analogs as MTOR inhibitors
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
AU2019266406A1 (en) 2018-05-09 2020-11-26 Ligachem Biosciences Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
WO2019222272A1 (en) * 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113227127A (zh) 2018-06-05 2021-08-06 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体
IL311437A (en) * 2018-06-07 2024-05-01 Seagen Inc Captures of camptothecin
CN112739340A (zh) 2018-07-23 2021-04-30 美真达治疗公司 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
WO2020056198A2 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
BR112021004689A2 (pt) * 2018-09-12 2021-06-08 Quiapeg Pharmaceuticals Ab conjugados glp-1 liberáveis
KR20220003572A (ko) 2019-04-24 2022-01-10 하이델베르크 파마 리서치 게엠베하 아마톡신 항체-약물 결합체 및 이의 용도
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
TW202116778A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩二號公司 作為治療劑之細胞毒素之肽結合物
EP3996749A1 (en) 2019-07-10 2022-05-18 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
WO2021030665A1 (en) 2019-08-15 2021-02-18 Silverback Therapeutics, Inc. Formulations of benzazepine conjugates and uses thereof
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
WO2021067861A1 (en) * 2019-10-04 2021-04-08 Seagen Inc. Camptothecin peptide conjugates
WO2021072330A1 (en) 2019-10-09 2021-04-15 Silverback Therapeutics, Inc. Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases
WO2021072203A1 (en) 2019-10-09 2021-04-15 Silverback Therapeutics, Inc. Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
CN110974975B (zh) * 2019-12-12 2023-10-20 成都百利多特生物药业有限责任公司 一种快速释放的抗体药物偶联物
CA3200812A1 (en) * 2020-12-04 2022-06-09 Qingsong GUO Antibody-drug conjugate, and intermediate thereof, preparation method thereof, and application thereof
KR20230121842A (ko) * 2020-12-18 2023-08-21 상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 Trop2를 표적으로 하는 항체 약물 접합체, 이의 제조방법 및 용도
WO2022126569A1 (zh) * 2020-12-18 2022-06-23 上海复旦张江生物医药股份有限公司 一种靶向b7-h3的抗体药物偶联物、其制备方法及应用
US20220193251A1 (en) 2020-12-23 2022-06-23 Ludwig-Maximilians-Universitaet Muenchen Cd30 targeting antibody drug conjugates and uses thereof
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
TW202304524A (zh) 2021-04-10 2023-02-01 美商普方生物製藥美國公司 Folr1結合劑、其結合物及使用方法
CA3216459A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.
WO2023092099A1 (en) 2021-11-19 2023-05-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
WO2023131219A1 (en) * 2022-01-06 2023-07-13 Virtuoso Binco, Inc. Conjugates, compositions and methods of use
WO2023194539A1 (en) 2022-04-07 2023-10-12 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index of amatoxin-antibody conjugates
WO2024025396A1 (ko) * 2022-07-28 2024-02-01 주식회사 레고켐 바이오사이언스 신규 오리스타틴 전구약물
WO2024052685A1 (en) 2022-09-09 2024-03-14 MyricX Pharma Limited Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy
CN117338949A (zh) * 2022-09-30 2024-01-05 成都百利多特生物药业有限责任公司 一种带有高稳定性亲水连接单元的奥瑞他汀类药物及其偶联物
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)
WO2024189048A1 (en) 2023-03-13 2024-09-19 Heidelberg Pharma Research Gmbh Subcutaneously administered antibody-drug conjugates for use in cancer treatment

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927070A (en) 1972-05-08 1975-12-16 Karoly Szabo M-(3,3-disubstituted ureido) phenyl {8 (substituted)methyl{9 {0 carbamates
US5851527A (en) 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
EP0848957A1 (en) 1995-09-08 1998-06-24 Kanebo Ltd. Fas LIGAND SOLUBILIZATION INHIBITOR
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
AU1607501A (en) 1999-11-15 2001-05-30 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
WO2005099768A2 (en) * 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
PT3248613T (pt) 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
AR069903A1 (es) 2007-11-30 2010-03-03 Medarex Inc Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
US20110152252A1 (en) * 2007-12-18 2011-06-23 Institut Curie Shiga toxin b-subunit/chemotherapeutics conjugates
ES2547552T3 (es) 2008-02-01 2015-10-07 Genentech, Inc. Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos
EP2306986B1 (en) 2008-06-26 2018-03-21 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
US9242013B2 (en) 2010-04-15 2016-01-26 Seattle Genetics Inc. Targeted pyrrolobenzodiazapine conjugates
EP2558475A1 (en) 2010-04-15 2013-02-20 Spirogen Sàrl Pyrrolobenzodiazepines used to treat proliferative diseases
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
BR112014009055B1 (pt) 2011-10-14 2021-12-14 Seattle Genetics, Inc. Compostos pirrolobenzodiazepinas, conjugados alvos, ligante de fármaco e uso dos ditos conjugados para tratar uma doença proliferativa
US9399073B2 (en) 2011-10-14 2016-07-26 Seattle Genetics, Inc. Pyrrolobenzodiazepines
US9526798B2 (en) 2011-10-14 2016-12-27 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
EA037203B1 (ru) 2012-05-15 2021-02-18 Сиэтл Джинетикс, Инк. Конъюгаты антитело-лекарственное средство с самостабилизирующимися линкерами
PT2917195T (pt) 2012-11-05 2018-02-09 Pfizer Análogos de spliceostatina
US9695189B2 (en) 2013-03-01 2017-07-04 Mark Quang Nguyen Chemical crosslinkers and compositions thereof
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
EP3265474A1 (en) 2015-03-05 2018-01-10 Sirenas LLC Cyclic peptide analogs and conjugates thereof

Also Published As

Publication number Publication date
IL246015B (en) 2020-03-31
IL301674A (en) 2023-05-01
KR20240010081A (ko) 2024-01-23
CA2932647C (en) 2022-06-14
US20220054650A1 (en) 2022-02-24
IL290330B1 (en) 2023-05-01
ZA202004099B (en) 2023-12-20
IL290330A (en) 2022-04-01
KR20220127364A (ko) 2022-09-19
JP2023055973A (ja) 2023-04-18
IL268595B (en) 2021-05-31
KR20160098303A (ko) 2016-08-18
AU2020281140B2 (en) 2022-09-08
JP7229202B2 (ja) 2023-02-27
JP2017500299A (ja) 2017-01-05
AU2022283652A1 (en) 2023-02-02
CA2932647A1 (en) 2015-06-25
IL282581B (en) 2022-03-01
CN105813653A (zh) 2016-07-27
JP6784790B2 (ja) 2020-11-11
JP2019081813A (ja) 2019-05-30
SG11201610465PA (en) 2017-01-27
ZA201604564B (en) 2022-09-28
IL290330B2 (en) 2023-09-01
JP6701077B2 (ja) 2020-05-27
AU2014369019B2 (en) 2020-09-17
US11116847B2 (en) 2021-09-14
CN111558049A (zh) 2020-08-21
CN111569086B (zh) 2024-06-21
CN111569086A (zh) 2020-08-25
KR102442906B1 (ko) 2022-09-14
WO2015095755A1 (en) 2015-06-25
IL268595A (en) 2019-10-31
MX2016007364A (es) 2016-09-08
CN105813653B (zh) 2020-06-26
TW201532616A (zh) 2015-09-01
AU2022283652B2 (en) 2024-10-03
CN111558049B (zh) 2024-06-21
NZ721877A (en) 2022-07-29
TWI727919B (zh) 2021-05-21
JP2020152733A (ja) 2020-09-24
US20160303254A1 (en) 2016-10-20
IL246015A0 (en) 2016-07-31
AU2020281140A1 (en) 2021-01-07
AU2014369019A1 (en) 2016-07-21
IL282581A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
ZA202004099B (en) Methylene carbamate linkers for use with targeted-drug conjugates
NZ758049A (en) Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
PH12015501422B1 (en) Hydrophilic self-immolative linkers and conjugates thereof
MX2017003886A (es) Conjugado radiofarmaceutico de un metabolito y un agente epr para tratar celulas tumorales.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2013005046A (es) Agentes citotoxicos que comprenden nuevos derivados de ansamitocina.
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
BR112019008854A2 (pt) ligantes contendo peptídeo para conjugados de anticorpo-fármaco
MX2021008334A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
PH12016502509A1 (en) Her2 antibody-drug conjugates
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
MX2013003452A (es) Conjugados de amatoxina con enlazantes mejorados.
MX2023013592A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
NZ725131A (en) Tubulysin derivatives
MX2016008448A (es) Conjugados de var2csa-farmaco.
GB2538023A (en) Targeted drug conjugates
MX2019004963A (es) Conjugados y particulas especificos del sstr y formulaciones de los mismos.
WO2014134457A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
MX2020010741A (es) Conjugados de fosfolipido-flavaglina y metodos para usar los mismos para la terapia dirigida al cancer.
SG10201805160UA (en) Methylene carbamate linkers for use with targeted-drug conjugates
TW201613651A (en) Pharmaceutical composition containing polymerized camptothecin derivative and polymerized hsp90 inhibitor derivative
EP4212181A3 (en) Methylene carbamate linkers for use with targeted-drug conjugates
IL261757A (en) Treatment of stem cells with chemotherapeutic agents conjugated to anti-matriptase antibodies using connecting parts that can be broken down in the animal's body